Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
The follow-up period will be 18 months or until death, loss to follow-up, or withdrawal, whichever comes first.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients aged 18 years or older at the time of informed consent.
Physician decision to treat the patient with dupilumab for prurigo nodularis (according to the country-specific prescribing information) made prior to and independently of the patient's participation in the study.
Patients able to understand and complete study-related questionnaires.
Patients provide voluntary informed consent to participate in the study before inclusion in the study.
You may not be if
Patients who have a contraindication to dupilumab according to the country-specific prescribing information label.
Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments.
Patients currently participating in any interventional clinical trial.
Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.
Clareo Health | Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
